Skip to content

Study on the Mechanism of SRPK1 Regulating Ferroptosis to promote trastuzumab Resistance in HER2+ Breast Cancer

Study on the Mechanism of SRPK1 Regulating Ferroptosis to promote trastuzumab Resistance in HER2+ Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126636
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-06-20
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor of the breast

Interventions

Observation Group:None
Control group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Pathological examination confirms HER2 positive: IHC result 3+ or 2+/ISH+; 2.Surgical resection or coarse needle aspiration is intended to obtain fresh tumor tissue; 3.Aged 18 to 75; 4.ECOG(Eastern Cooperative Oncology Group):0~3; 5.Voluntarily participate in this clinical trial, understand and abide by the research procedures and have signed the informed consent form; 6.There are no relative or absolute contraindications for surgery;

Exclusion criteria

Exclusion criteria: 1.Received neoadjuvant therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) before the operation; 2.Preoperative assessment or intraoperative exploration reveals that insufficient tumor tissue cannot be obtained (including inability to resect, etc.); 3.Women planning to become pregnant or women who are breastfeeding; 4.Having participated in clinical trials of other anti-tumor drugs or having received chemotherapy/targeted drug therapy within four weeks prior to signing the informed consent form; 5.The sample quality does not meet the standards for tumor organoid modeling; 6.The modeling of tumor organoids failed; 7.Immune deficiency or severe bone marrow suppression; 8.The patient already has serious liver and kidney diseases, cardiovascular diseases, blood disorders, etc; 9.Illegal use of drugs or chronic alcohol abuse or a total daily alcohol intake of more than 50 g/d; 10.Lack of autonomy, inability to walk, or inability to participate in the 6-month follow-up;

Design outcomes

Primary

MeasureTime frame
SRPK1 expression level;mRNA expression level;Protein expression level;

Countries

China

Contacts

Public ContactLiu Chunpin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

liucpwhxh@hust.edu.cn+86 138 7104 1729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026